NASDAQ:QURE - Uniqure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$31.36 +0.13 (+0.42 %)
(As of 01/20/2019 04:00 PM ET)
Previous Close$31.36
Today's Range$30.41 - $31.87
52-Week Range$17.44 - $43.23
Volume336,266 shs
Average Volume301,050 shs
Market Capitalization$1.17 billion
P/E Ratio-10.67
Dividend YieldN/A
Beta0.75
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-566-7394

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.11 million
Book Value$2.90 per share

Profitability

Net Income$-79,260,000.00
Net Margins-725.04%

Miscellaneous

Employees202
Market Cap$1.17 billion
OptionableOptionable

Uniqure (NASDAQ:QURE) Frequently Asked Questions

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) announced its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.03. The biotechnology company had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. View Uniqure's Earnings History.

When is Uniqure's next earnings date?

Uniqure is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Uniqure.

What price target have analysts set for QURE?

10 equities research analysts have issued 1-year price objectives for Uniqure's shares. Their predictions range from $30.00 to $76.00. On average, they expect Uniqure's share price to reach $55.8889 in the next year. This suggests a possible upside of 78.2% from the stock's current price. View Analyst Price Targets for Uniqure.

What is the consensus analysts' recommendation for Uniqure?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.

What are Wall Street analysts saying about Uniqure stock?

Here are some recent quotes from research analysts about Uniqure stock:
  • 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (1/17/2019)
  • 2. HC Wainwright analysts commented, "Our $60 price target vs. prior $48, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical update, refer to our November 15, 2018 note for details, vs. 65% POS previously and anticipate commercial launch during 2H-2021, with a lower NAB-based exclusion of 5% vs. prior 10%, and model risk-adjusted peak sales of roughly $1.14B (vs. $981M previously), during 2028. We assume a launch price of $850K (vs." (11/26/2018)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and are raising our 12- month price target to $65 from $58. This morning, uniQure announced initial top- line data from the Phase 2b dose-confirmation study of AMT-061 for the treatment of severe hemophilia B. Data from three patients show a mean factor IX (FIX) level of 31% six weeks post-administration. Importantly, there were no bleeding events, use of factor infusions, or required immunosuppression. The data met uniQure’s projected goals in FIX activity levels, which we believe supports moving forward with dosing in the Phase 3 HOPE-B trial. We expect to hear additional details at the company November 19." (11/15/2018)
  • 4. Chardan Capital analysts commented, "We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels." (10/18/2018)

Has Uniqure been receiving favorable news coverage?

Headlines about QURE stock have been trending neutral this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Uniqure earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are some of Uniqure's key competitors?

Who are Uniqure's key executives?

Uniqure's management team includes the folowing people:
  • Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 47)
  • Dr. Sander Van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & Gen. Mang. of Amsterdam (Age 65)
  • Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Scott T. McMillan, Chief Operating Officer (Age 60)

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $31.36.

How big of a company is Uniqure?

Uniqure has a market capitalization of $1.17 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.

What is Uniqure's official website?

The official website for Uniqure is http://www.uniqure.com.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]


MarketBeat Community Rating for Uniqure (NASDAQ QURE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  478 (Vote Outperform)
Underperform Votes:  324 (Vote Underperform)
Total Votes:  802
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel